Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

186.66
-14.2100-7.07%
Volume:3.82M
Turnover:708.58M
Market Cap:40.01B
PE:-20.92
High:199.64
Open:198.51
Low:180.52
Close:200.87
52wk High:224.31
52wk Low:46.16
Shares:214.34M
Float Shares:185.00M
Volume Ratio:2.86
T/O Rate:2.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:15.35
PE(LYR):-31.37

Loading ...

Revolution Medicines Falls on Pancreatic Cancer Drug Data Concerns

Reuters
·
42 mins ago

Revolution trading down after daraxonrasib review docs, says Stifel

TIPRANKS
·
2 hours ago

Movement Alert|Revolution Medicines, Inc. Falls 5.28% in Regular Trading, Biotech Sector Weakness Pressures Shares

Market Focus
·
Yesterday

RBC Raises Price Target on Revolution Medicines to $259 From $251, Keeps Outperform Rating

MT Newswires Live
·
Yesterday

Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative

Simply Wall St.
·
Yesterday

Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

GlobeNewswire
·
Oct 07

Movement Alert|Revolution Medicines, Inc. Falls 5.23% in Regular Trading, Biotechnology Sector Weakness Drags Down Shares

Market Focus
·
Oct 06

Maintained Buy on Revolution Medicines: Strong RAS Franchise Momentum and ESMO GI 2026 Data Support Unchanged $315 Price Target

TIPRANKS
·
Oct 05

Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer

Reuters
·
Oct 05

Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer

THOMSON REUTERS
·
Oct 05

Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288

THOMSON REUTERS
·
Oct 05

Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares

Reuters
·
Oct 02

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Sells USD 743,436 in Common Shares

Reuters
·
Sep 29

Revolution Medicines Price Target Announced at $318.00/Share by Brookline Capital

Dow Jones
·
Sep 29

Buy Rating Reiterated on Revolution Medicines as KRAS G12D Lead Strengthens; $315 Price Target Maintained

TIPRANKS
·
Sep 29

Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says

MT Newswires Live
·
Sep 28

Bernstein Sticks to Their Hold Rating for Revolution Medicines (RVMD)

TIPRANKS
·
Sep 26

Movement Alert|Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Multiple Banks Raise Price Targets Amid FDA Breakthrough Therapy Designation

Market Focus
·
Sep 25

Revolution Medicines Director Elizabeth M. Anderson Disposes of $1,949,321.86 in Common Shares

Reuters
·
Sep 25

Movement Alert|Revolution Medicines, Inc. Rises 5.09% in Regular Trading, Multiple Banks Raise Price Targets Following FDA Breakthrough Therapy Designation

Market Focus
·
Sep 25